Prelude Therapeutics Inc
PRLD · XNASCIK 1678660fmd_17PH6W8QX341NM0EG71EM84R42Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2019 to Jun 30, 2026, 30 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | – | 7 | 12 |
| Research and development | 24 | 48 | 87 | 93 | 103 | 118 | 94 |
| Total operating expenses | 28 | 59 | 114 | 124 | 132 | 147 | 117 |
| Operating income | (28) | (59) | (114) | (124) | (132) | (140) | (105) |
| Other non-operating income (expense) | 1 | 2 | 2 | 8 | 10 | 13 | 5 |
| Income before taxes | – | – | – | – | – | (127) | (100) |
| Income tax expense | – | – | – | – | – | 0 | 0 |
| Net income from continuing operations | – | – | – | – | – | (127) | (100) |
| Net income | (28) | (57) | (112) | (115) | (122) | (127) | (99) |